Summary
A low-intervention policy for Hickman catheter maintenance has been evaluated and found to be safe and cost effective. A simple, lightweight, disposable device has been used for 24-hour ambulatory home infusion. Implementation of this policy as part of a prospective randomized trial of single-agent chemotherapy in advanced breast cancer has demonstrated that slow intravenous infusion reduces the acute toxicity of epirubicin when compared with bolus injection.
10 ml normal saline and the infusor connected. The patient disconnects the infusor the following day and 'recaps' the line without flushing it.
To determine the merits of this method of treatment, we are conducting a randomized trial of weekly epirubicin given either by 24-hour infusion or bolus injection. Thirty-three patients with advanced breast cancer are at present assessable; 14 have received infusion therapy using a total of 149 infusors. There have been no mechanical failures by the infusor. Introduction A plateau has been reached in the response rates achieved by various single and combination regimens of chemotherapy in advanced breast cancer", Whilst the anthracycline Adriamycin remains the single most effective drug for treating breast cancer, it is extremely toxic when given by the conventional 3-weekly scheduling of large doses. Side effects may be reduced by weekly administration of smaller doses'', and by the use of analogues. Epirubicin is structurally similar to Adriamycin and has equivalent efficacy but reduced toxicity", It has also been suggested that the acute and chronic toxicity is dependent upon the peak plasma dose of the anthracycline, whilst response rate appears to be independent, and may be improved by prolonged exposure to low doses as more cells are treated at vulnerable stages of their cycle".
Infusion therapy has previously been considered difficult. Our survey of London hospitals has revealed a wide variety of Hickman line flushing and exitsite dressing policies. By adopting a low maintenance policy for Hickman catheters, without exit-site dressings and only flushing the lines weekly with normal saline, we have reduced both cost and time. Traditional Hickman catheter maintenance with daily dressing and heparinization has been estimated to cost £113 per month; by implementation of a lowmaintenance regimen the cost is reduced to £2 per month.
Rather than heavy, expensive mechanical pumps, infusions through the catheters have incorporated 'Travenol Infusors'. These are small, light, disposable cylinders. Both the force to propel and a.reservoir for the solution are provided by an elastomeric balloon.
Method
When the patient attends the clinic the Hickman line is used for blood sampling; it is then flushed with Table 1 . At present there is no significant difference in response rates between the two groups.
Conclusion
We have encountered no additional problems as a result of using a low-intervention regimen for the care of Hickman lines. Our initial experience has indicated that infusors may reduce acute toxicity. In addition, treatment time has decreased and needle phobia and the risk of extravasation have not been encountered. There have been nocases ofcardiotoxicity in either group.
Infusion anthracyclines appear to offer safe, less toxic chemotherapy with an improved quality of life. Larger patient numbers are required in order to determine whether response rates are improved, and this trial is still continuing to recruit patients.
